Skip to content
Brand AI

Sino Biological

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2023

    Sino Biological criticized, warned over cash management review and disclosure failures

    In 2022, Sino Biological used idle self-owned funds for cash management without timely performing board and shareholders' meeting review and information disclosure obligations; in 2023, the Shenzhen Stock Exchange circulated criticism of the company and board secretary Feng Tao, and in 2024 the Beijing Securities Regulatory Bureau issued a warning letter. The company was criticized and warned, and the matter was recorded in its integrity file.

    Source